We found that the genes induced by such factors are significantly reduced in CLL cells of patients treated with cirmtuzumab from levels noted prior to therapy, indicating that cirmtuzumab can repress expression of genes induced by activation of ERK1/2 in vivo. The gene discussed is MAPK3; the disease is B-cell chronic lymphocytic leukemia.